Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075608 | 0.88 | GRIN2B (0.33) | CCR4GRIN2BGRIN1 | |
| SCHEMBL22075612 | 0.88 | GRIN2B (0.33) | CCR4GRIN2BGRIN1 | |
| SCHEMBL22075812 | 0.77 | PTGS2 (0.36) | CCR4CCR5GRIN2BGRIN1KMT2A | |
| SCHEMBL22075669 | 0.74 | GRIN2B (0.33) | GRIN2BGRIN1 | |
| SCHEMBL22075692 | 0.70 | PTGS2 (0.36) | GRIN2BGRIN1 | |
| SCHEMBL25375611 | 0.60 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL30552651 | 0.60 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL10448855 | 0.58 | TSHR (0.48) | MEN1KMT2A | |
| SCHEMBL30552772 | 0.57 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL9193008 | 0.52 | CYP2A6 (0.50) | PDGFRBPDGFRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |